This is a paid press release. Contact the press release distributor directly with any inquiries.
DGEN TECHNOLOGIES ACQUIRES EXCLUSIVE LICENCE TO HUMANOS ARTIFICIAL INTELLIGENCE TECHNOLOGY
VANCOUVER, BC, Nov. 12, 2026 /CNW/ — DGEN Technologies Corp. (CSE: DGEN) (“DGEN” or the “Company“) is pleased to announce that it has entered into a licence agreement dated November 12, 2026 (the “Licence Agreement“) with HumanOS Technologies Inc. (“HumanOS“), an arm’s length company, pursuant to which HumanOS has granted the Company an exclusive and irrevocable licence (the “Licence“) to its artificial intelligence software, automation technology and related assets (the “Transaction“).
The licensed assets include the software, source code, systems, platforms and tools developed and operated by HumanOS under the “HumanOS” name, including the HumAIn, Matspace, Media Studio and Automation Lab products and the HumanOS scan tool, together with the HumanOS trade name, the 1humanos.com domain and associated websites and social media accounts, client and customer lists (names and contact details only) and related information and documentation (collectively, the “Licensed Assets“). The Licence permits the Company and its affiliates to use, commercialize, further develop and sublicense the Licensed Assets. HumanOS retains ownership of the Licensed Assets, while any improvements to the Licensed Assets developed by or for the Company will be owned by the Company.
In consideration for the Licence, the Company will issue an aggregate of 4,000,000 common shares in the capital of the Company (the “Consideration Shares“) at a deemed price of $0.25 per Consideration Share and 4,000,000 common share purchase warrants (the “Consideration Warrants“). Each Consideration Warrant will be exercisable to acquire one common share of the Company at an exercise price of $0.32 per share for a period of three years from the date of issuance. The Consideration Shares and Consideration Warrants, and any shares issued on exercise of the Consideration Warrants, will be subject to a statutory hold period of four months and one day from the date of issuance in accordance with applicable securities laws.
Closing of the Transaction, including the issuance of the Consideration Shares and Consideration Warrants (“Closing”), remains subject to the approval of the Canadian Securities Exchange (the “CSE”) and the satisfaction of certain other conditions, including the delivery to the Company of thesing is expected to occur in the coming week or weeks. No finder’s fees are payable in connection with the Transaction
About DGEN Technologies Corp.
